Lord's Mark Industries outlines strategic expansion across global healthcare, advanced diagnostics & oncology; targets ₹1,550 Crore revenue in FY2027

India’s healthcare landscape is undergoing a significant shift, with growing demand for affordable advanced diagnostics, specialised cancer care, precision medicine and technology-led healthcare solutions extending beyond major urban centres. At the same time, Indian healthcare companies are increasingly looking to build globally competitive platforms by combining domestic manufacturing capabilities with international market access.

Against this backdrop, Lord’s Mark Industries Limited is entering a new phase of expansion, outlining a healthcare-focused growth strategy spanning diagnostics, oncology, medical devices and global markets, while proposing to separate its renewable energy and LED business into a standalone entity to create greater focus and flexibility across its businesses.

For FY2027, the Company expects consolidated revenue of at least ₹1,550 crore, representing over 20% growth compared to FY2026, and Profit After Tax (PAT) of at least ₹178 crore at a margin of 11.4%, reflecting a margin expansion of over 200 basis points.


The majority of FY2027 growth will be driven by core operations across in-vitro diagnostics and renewable energy, with further operational momentum expected from FY2028 onward through the commercialisation of its sickle cell testing business and medical device platforms, Onco Spectra and TB Truth.

To optimise capital allocation and allow standalone healthcare evaluation, the Board of Directors proposes to demerge its renewable energy and LED business into a separate entity, Lords Shakti Power Limited, by March 2027. Lord's Mark Industries will hold a 60% stake in the resulting company, while existing shareholders will receive mirror equity. The demerged energy business will also expand into power transmission through transformer manufacturing.

On healthcare delivery and partnerships, Lord's Mark is entering into an exclusive agreement with a leading global manufacturer to bring CAR-T cell therapy to India across five specialized centers, starting with Mumbai and Bengaluru by March 2027, significantly lowering treatment costs to widen patient access.

Through its new subsidiary, Lords Mark Medicure Limited, the company is launching an oncology hospital network in tier-2 cities to address critical care shortages, beginning with two pilot 70-bed hospitals in Vapi and Solapur supported by a planned ₹200 crore debt raise in December 2026. Additionally, the Company plans to establish 50 company-operated dialysis centers across India by March 2027 equipped with its proprietary RENALOS machines to transition towards recurring service revenues.

Expanding its international footprint, the Company incorporated Lords Mark Industries UK Limited—the first Indian company registered under the India-UK Free Trade Agreement—and is in the process of establishing Lords Mark Industries Swiss Limited.

Both entities will operate captive pathology laboratories supplied entirely by Indian manufacturing facilities while distributing diagnostic products across European markets. An application for NHS approval has been submitted. The subsidiaries open a developed-market channel for the Company’s IVD manufacturing base at international price points.

On the innovation front, patient trials have been completed for the OneDNA genomic testing platform following ICMR approval, while the Biomescan Analytics Platform became the first software as a medical device (SaMD) in India to receive a manufacturing licence under the Medical Devices Rules, 2017.

Commenting on the developments, Mr. Sachidanand Upadhyay, Managing Director, Lord's Mark Industries Ltd., stated: "Lord's Mark today stands at the most important inflection point in its history. Over the past decade, we have built profitable, scaled businesses in diagnostics and renewable energy, the foundations of which now fund our next chapter.

The guidance we have issued reflects the strength of our existing operations, with top-line growth of at least 20% and PAT (Profit After Tax ) growth of at least 50%. The subsequent announcements are what we build on top of them: cancer care reaching India's rural districts, advanced CAR-T therapy at affordable prices for Indian patients, and Indian-made diagnostics serving laboratories from the UK to Switzerland. Healthcare in India is moving from scarcity to access, and Lord's Mark intends to be one of the companies that makes that happen."

The next phase of Lord’s Mark’s growth will therefore be defined not just by scale, but by its ability to translate its existing manufacturing and diagnostics capabilities into a broader healthcare ecosystem.

With investments across advanced diagnostics, specialised cancer care, medical devices and international markets, alongside a more focused corporate structure following the proposed energy demerger, the company is positioning itself to build multiple growth engines over the coming years. If executed as planned, these initiatives could strengthen Lord’s Mark’s presence across the healthcare value chain while expanding the reach of Indian-made healthcare solutions in both domestic and global markets.

For more details visit :- https://lordsmark.com/

Disclaimer - The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.